Meridian Bioscience (Nasdaq:VIVO) - Aktienkurs, Nachrichten und Analyse

VIVO Aktienübersicht

Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide.

Über das Unternehmen

VIVO grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	4/6
Künftiges Wachstum	0/6
Vergangene Leistung	1/6
Finanzielle Gesundheit	6/6
Dividenden	0/6

Belohnungen

25.5% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Risikoanalyse

Die Gewinnspannen (12.7%) sind niedriger als im Vorjahr (22.5%)

Große einmalige Posten, die sich auf die Finanzergebnisse auswirken

Meridian Bioscience, Inc. Wettbewerber

STAAR Surgical

NasdaqGM:STAA

US$2.0b

UFP Technologies

NasdaqCM:UFPT

US$2.0b

Atrion

NasdaqGS:ATRI

US$792.0m

Embecta

NasdaqGS:EMBC

US$718.6m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Meridian Bioscience
Historische Aktienkurse
Aktueller Aktienkurs	US$33.97
52-Wochen-Hoch	US$34.38
52-Wochen-Tief	US$21.09
Beta	0.23
11 Monat Veränderung	2.29%
3 Monate Veränderung	6.02%
1 Jahr Veränderung	54.34%
33 Jahre Veränderung	295.23%
5 Jahre Veränderung	128.75%
Veränderung seit IPO	6,030.20%

Aktuelle Nachrichten und Updates

Recent updates

Meridian Bioscience Non-GAAP EPS of $0.16 misses by $0.01, revenue of $67.8M beats by $1M

Aug 05

Many Would Be Envious Of Meridian Bioscience's (NASDAQ:VIVO) Excellent Returns On Capital

Jun 09

Meridian Bioscience: Deceptively Priced

Mar 14

Meridian Bioscience (NASDAQ:VIVO) Looks To Prolong Its Impressive Returns

Feb 03

These 4 Measures Indicate That Meridian Bioscience (NASDAQ:VIVO) Is Using Debt Safely

Jul 19

If The COVID-19 Delta Variant Spreads This Fall, Meridian Is Still A Buy

Jul 08

Meridian Bioscience (NASDAQ:VIVO) Might Become A Compounding Machine

May 10

Meridian Bioscience, Inc. 2021 Q2 - Results - Earnings Call Presentation

May 08

Meridian Bioscience (NASDAQ:VIVO) Seems To Use Debt Rather Sparingly

Mar 31

Have Insiders Been Buying Meridian Bioscience, Inc. (NASDAQ:VIVO) Shares?

Mar 11

Investors Who Bought Meridian Bioscience (NASDAQ:VIVO) Shares A Year Ago Are Now Up 185%

Feb 24

Need To Know: Analysts Are Much More Bullish On Meridian Bioscience, Inc. (NASDAQ:VIVO) Revenues

Feb 09

Meridian expands production capacity for COVID-19 tests with NIH funding

Feb 03

Should We Be Excited About The Trends Of Returns At Meridian Bioscience (NASDAQ:VIVO)?

Jan 27

Does Meridian Bioscience (NASDAQ:VIVO) Deserve A Spot On Your Watchlist?

Jan 13

Aktionärsrenditen

	VIVO	US Medical Equipment	US Markt
7D	0.06%	0.6%	0.5%
1Y	54.3%	0.03%	23.9%

Rendite im Vergleich zur Industrie: VIVO übertraf die Branche US Medical Equipment, die im vergangenen Jahr eine Rendite von 5.5 erzielte.

Rendite vs. Markt: VIVO übertraf den Markt US, der im vergangenen Jahr eine Rendite von 25.6 erzielte.

Preisvolatilität

Is VIVO's price volatile compared to industry and market?
VIVO volatility
VIVO Average Weekly Movement	2.3%
Medical Equipment Industry Average Movement	7.8%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.4%
10% least volatile stocks in US Market	2.8%

Stabiler Aktienkurs: VIVO hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: VIVODie wöchentliche Volatilität (2%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1976	704	Jack Kenny	www.meridianbioscience.com

Meridian Bioscience, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Meridian Bioscience im Vergleich zum Marktanteil des Unternehmens?
VIVO grundlegende Statistiken
Marktanteil	US$1.49b
Gewinn(TTM)	US$42.46m
Umsatz(TTM)	US$333.02m

35.2x

Kurs-Gewinn-Verhältnis

4.5x

Kurs-Umsatz-Verhältnis

Ist VIVO zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
VIVO Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$333.02m
Kosten der Einnahmen	US$144.66m
Bruttogewinn	US$188.36m
Sonstige Ausgaben	US$145.90m
Umsatz	US$42.46m

Zuletzt gemeldete Gewinne

Sep 30, 2022

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	0.96
Bruttomarge	56.56%
Nettogewinnspanne	12.75%
Schulden/Eigenkapital-Verhältnis	6.8%

Wie hat sich VIVO auf lange Sicht entwickelt?

Historische Performance und Vergleiche

VIVO Aktienübersicht

Belohnungen

Risikoanalyse

Meridian Bioscience, Inc. Wettbewerber

NasdaqGM:STAA

US$2.0b

NasdaqCM:UFPT

US$2.0b

NasdaqGS:ATRI

US$792.0m

NasdaqGS:EMBC

US$718.6m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Meridian Bioscience, Inc. Drives Democratization of Next-Generation Sequencing with Reagents Enabling Ambient Temperature Shipping and Storage of Sequencing Kits

Meridian Bioscience Continues Expansion of H. Pylori Diagnostic Testing Solutions with Fda Clearance of Premier Hpsa Flex

Meridian Bioscience, Inc. announced that it expects to receive KRW 258.225164381 billion in funding

SD BioSensor, Inc (KOSE:A137310) (SDB) and SJL Partners completed the acquisition of Meridian Bioscience, Inc. (NasdaqGS:VIVO) from Impactive Capital LP, BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc, Royce & Associates, LP and others.

Independent Director exercised options to buy US$285k worth of stock.

Meridian Bioscience, Inc. to Report Q4, 2022 Results on Nov 22, 2022

Recent updates

Meridian Bioscience, Inc. Drives Democratization of Next-Generation Sequencing with Reagents Enabling Ambient Temperature Shipping and Storage of Sequencing Kits

Meridian Bioscience Continues Expansion of H. Pylori Diagnostic Testing Solutions with Fda Clearance of Premier Hpsa Flex

Meridian Bioscience, Inc. announced that it expects to receive KRW 258.225164381 billion in funding

SD BioSensor, Inc (KOSE:A137310) (SDB) and SJL Partners completed the acquisition of Meridian Bioscience, Inc. (NasdaqGS:VIVO) from Impactive Capital LP, BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc, Royce & Associates, LP and others.

Independent Director exercised options to buy US$285k worth of stock.

Meridian Bioscience, Inc. to Report Q4, 2022 Results on Nov 22, 2022

Full year 2022 earnings: EPS exceeds analyst expectations

Price target increased to US$34.00

Insufficient new directors

Impactive Capital Provides Information to Shareholders of Meridian Bioscience

Consensus EPS estimates fall by 31%

Meridian Bioscience, Inc. Provides Update on Earnings Guidance for the Fiscal Year 2022

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Meridian Bioscience Non-GAAP EPS of $0.16 misses by $0.01, revenue of $67.8M beats by $1M

Meridian Bioscience, Inc. Receives Re-Authorization from FDA for its Revogene® SARS-CoV-2 Molecular Assay

Meridian Bioscience: High-Probability Merger Arbitrage

SD BioSensor, Inc (KOSE:A137310) (SDB) and SJL Partners (collectively, the "Consortium") entered into a definitive merger agreement to acquire Meridian Bioscience, Inc. (NasdaqGS:VIVO) for $1.5 billion.

Meridian Bioscience downgraded at William Blair on $1.53B acquisition

Meridian Bioscience (NASDAQ:VIVO) Has A Pretty Healthy Balance Sheet

Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from Russell 2000 Value-Defensive Index

Meridian Bioscience: Correctly Valued

President exercised options and sold US$1.1m worth of stock

Meridian Launches New qPCR Master Mixes for Stool Samples to Accelerate Development of Molecular Assays

Many Would Be Envious Of Meridian Bioscience's (NASDAQ:VIVO) Excellent Returns On Capital

Meridian Bioscience, Inc. Responds to the Monkeypox Outbreak with Its Inhibitor-Tolerant qPCR Master Mixes for the Development of Molecular Tests

Meridian Bioscience, Inc. Launches Lyo-Ready™ Saliva-Specific Isothermal Amplification Master Mixes for Direct Detection of DNA & RNA in Point of Care Diagnostic Assays

Insufficient new directors

Meridian Bioscience, Inc. Provides Preliminary Revenue Guidance for the Second Quarter of Fiscal 2022

Meridian Bioscience: Deceptively Priced

Meridian Bioscience, Inc. Names Andy Kitzmiller as Executive Vice President

Magellan Diagnostics Resumes Distribution of Leadcare® II Test Kits

Investor sentiment improved over the past week

Price target increased to US$30.00

Meridian Bioscience, Inc. Raises Earnings Guidance for the Full Fiscal Year 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Meridian Bioscience (NASDAQ:VIVO) Looks To Prolong Its Impressive Returns

Meridian Bioscience Launches Lyo-Ready qPCR Saliva-Specific Master Mixes for DNA & RNA Direct Detection

Meridian Bioscience, Inc. Announces Board Changes

Key Executive exercised options to buy US$157k worth of stock.

Meridian Bioscience, Inc. Receives FDA-Clearance for the Curian® Campy Assay

Full year 2021 earnings released: EPS US$1.65 (vs US$1.08 in FY 2020)

Insufficient new directors

Insufficient new directors

Price target decreased to US$27.00

Meridian Bioscience, Inc. Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detection of DNA or RNA from Saliva Samples

Price target decreased to US$30.50

Third quarter 2021 earnings released: EPS US$0.27 (vs US$0.64 in 3Q 2020)

These 4 Measures Indicate That Meridian Bioscience (NASDAQ:VIVO) Is Using Debt Safely

Investor sentiment deteriorated over the past week

Meridian Bioscience, Inc. Provides Preliminary Revenue Guidance for the Third Quarter of Fiscal 2021

If The COVID-19 Delta Variant Spreads This Fall, Meridian Is Still A Buy

Meridian Bioscience, Inc. Announces Launch of the Lyo-Ready RT-LAMP Mix

Meridian Bioscience, Inc. Improves Field-Testing in AgBio with its New Air-Dryable™ qPCR Mix for Crude Plant Samples

Consensus forecasts updated

Meridian Bioscience (NASDAQ:VIVO) Might Become A Compounding Machine

Second quarter 2021 earnings released: EPS US$0.61 (vs US$0.22 in 2Q 2020)

Meridian Bioscience, Inc. Provides Revenue Guidance for the Fiscal Year 2021

Meridian Bioscience, Inc. 2021 Q2 - Results - Earnings Call Presentation

Meridian Bioscience, Inc. Announces the Launch of the Lyo-Ready DNA LAMP Mix

Erträge & Einnahmen